Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JAC/DKH050PMID 14726431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Practical Considerations and Guidelines for the Management of Community-Acquired Pneumonia

  2012cited by this paper
• Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis

  2004cited by this paper
• Introduction: standards of antibacterial performance.

  2004cited by this paper
• Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.

  2004cited by this paper
• Elements of design: the knowledge on which we build.

  2004cited by this paper
• Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.

  2004cited by this paper
• British Thoracic Society

  2004cited by this paper
• A review of the antimicrobial activity of clavulanate.

  2003cited by this paper
• How can we predict bacterial eradication?

  2003cited by this paper
• Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

  2003cited by this paper
• Journal of Antimicrobial Chemotherapy

  2003cited by this paper
• Introduction: the goals of antimicrobial therapy.

  2003cited by this paper
• Why do we need to eradicate pathogens in respiratory tract infections?

  2003cited by this paper
• The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

  2003cited by this paper
• Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.

  2003cited by this paper
• Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

  2002cited by this paper
• Treatment of drug-resistant pneumococcal pneumonia.

  2002cited by this paper
• Emergence of macrolide resistance during treatment of pneumococcal pneumonia.

  2002cited by this paper
• Bacterial eradication in the treatment of otitis media.

  2002cited by this paper
• Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.

  2002cited by this paper
• Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

  2002cited by this paper
• Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.

  2002cited by this paper
• In Vitro Selection of Resistance in Haemophilus influenzae by Amoxicillin-Clavulanate, Cefpodoxime, Cefprozil, Azithromycin, and Clarithromycin

  2002cited by this paper
• Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence.

  2002cited by this paper
• Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media.

  2002cited by this paper
• A Multinational, Multicentre, Non-Blinded, Randomized Study of Moxifloxacin Oral Tablets Compared with Co-Amoxiclav Oral Tablets in the Treatment of Acute Exacerbation of Chronic Bronchitis

  2001cited by this paper
• Usefulness of Betalactam Therapy for Community-Acquired Pneumonia in the Era of Drug-Resistant Streptococcus pneumoniae: A Randomized Study of Amoxicillin-Clavulanate and Ceftriaxone

  2001cited by this paper
• The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.

  2001cited by this paper
• Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

  2001cited by this paper
• The hidden impact of antibacterial resistance in respiratory tract infection. Steering an appropriate course: principles to guide antibiotic choice.

  2001cited by this paper
• What should the initial antibiotherapy for acute community acquired pneumonia be? How should it be reassessed in case of failure, given the evolution of responsible pathogens and the resistance of pneumococci? Should combined treatment be used?

  2001cited by this paper
• Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media

  2001cited by this paper
• Clinical failures: the tip of the iceberg?

  2001cited by this paper
• Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media.

  2001cited by this paper
• Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial.

  2001cited by this paper
• Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

  2001cited by this paper
• Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media

  2000cited by this paper
• Efficacy and safety of amoxycillin/clavulanate (Augmentin) twice daily versus three times daily in the treatment of acute otitis media in children. The Augmentin 454 Study Group.

  2000cited by this paper
• Efficacy and Safety of Amoxycillin/Clavulanate (Augmentin®) Twice Daily Versus Three Times Daily in the Treatment of Acute Otitis Media in Children

  2000cited by this paper
• Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters.

  2000cited by this paper
• Efficacy of High-Dose Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains ofStreptococcus pneumoniae

  1999cited by this paper
• Two Pharmacodynamic Models for Assessing the Efficacy of Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumoniae

  1999cited by this paper
• Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?

  1999cited by this paper
• Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

  1999cited by this paper
• EFFICACY OF TWICE‐DAILY AMOXYCILLIN/CLAVULANATE IN LOWER RESPIRATORY TRACT INFECTIONS

  1999cited by this paper
• In Vitro Development of Resistance to Five Quinolones and Amoxicillin-Clavulanate in Streptococcus pneumoniae

  1999cited by this paper
• Efficacy and tolerability of cefprozil versus amoxicillin/clavulanate for the treatment of adults with severe sinusitis.

  1998cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper
• Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.

  1998cited by this paper
• Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae.

  1998cited by this paper
• In Vitro Activities of Oral β-Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance

  1998cited by this paper
• Forty years of beta-lactam research.

  1998cited by this paper
• In Vitro Selection of Resistance to Four β-Lactams and Azithromycin in Streptococcus pneumoniae

  1998cited by this paper
• Microbiology of acute and chronic sinusitis in children and adults.

  1998cited by this paper
• Bacteriological Efficacies of Three Macrolides Compared with Those of Amoxicillin-Clavulanate againstStreptococcus pneumoniae and Haemophilus influenzae

  1998cited by this paper
• Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children.

  1997cited by this paper
• Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies

  1997cited by this paper
• Diagnóstico y tratamiento de la neumonía adquirida en la comunidad

  1997cited by this paper
• Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group.

  1997cited by this paper
• Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.

  1997cited by this paper
• Strategies to minimize the development of antibiotic resistance.

  1997cited by this paper
• Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children

  1997cited by this paper
• Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group.

  1997cited by this paper
• In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral beta-lactam antibiotics is associated with alterations of PBP2x

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.

  1996cited by this paper
• A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander Project.

  1996cited by this paper
• EFFICACY OF TWICE‐DAILY AMOXYCILLIN/CLAVULANATE (‘AUGMENTIN‐DUO’ 400/57) IN MILD TO MODERATE LOWER RESPIRATORY TRACT INFECTION IN CHILDREN

  1996cited by this paper
• Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study.

  1996cited by this paper
• Clinical pharmacokinetics of amoxicillin and clavulanate.

  1996cited by this paper
• Antimicrobial resistance issues of the future.

  1996cited by this paper
• Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis.

  1995cited by this paper
• Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment.

  1995cited by this paper
• Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects.

  1994cited by this paper
• Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.

  1994cited by this paper
• Penicillin-binding protein 2b of Streptococcus pneumoniae in piperacillin-resistant laboratory mutants

  1994cited by this paper
• Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992.

  1993cited by this paper
• Pneumococcal resistance to antibiotics

  1990cited by this paper
• The pharmacokinetics and sputum penetration of ampicillin and amoxycillin following simultaneous i.v. administration.

  1990cited by this paper
• Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man.

  1990cited by this paper
• Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

  1990cited by this paper
• Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.

  1990cited by this paper
• Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

  1988cited by this paper
• Pharmacokinetics and Urinary Excretion of Clavulanic Acid After Oral Administration of Amoxicillin and Potassium Clavulanate

  1984cited by this paper
• Amoxicillin and Potassium Clavulanate: An Antibiotic Combination Mechanism of Action, Pharmacokinetics, Antimicrobial Spectrum, Clinical Efficacy and Adverse Effects

  1984cited by this paper
• Treatment of chancroid by clavulanic acid with amoxycillin in patients with beta-lactamase-positive Haemophilus ducreyi infection.

  1982cited by this paper
• TREATMENT OF CHANCROID BY CLAVULANIC ACID WITH AMOXYCILLIN IN PATIENTS WITH β-LACTAMASE-POSITIVE HAEMOPHILUS DUCREYI INFECTION

  1982cited by this paper
• Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination.

  1982cited by this paper
• Activities of amoxicillin and clavulanic acid combinations against urinary tract infections

  1982cited by this paper
• Amoxicillin-clavulanic acid in treatment of urinary tract infection due to gram-negative bacteria resistant to penicillin

  1981cited by this paper
• Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria.

  1981cited by this paper
• The combination of clavulanic acid and amoxycillin (Augmentin) in the treatment of patients infected with penicillinase producing gonococci.

  1981cited by this paper
• High performance liquid chromatographic determination of clavulanic acid in human urine.

  1981cited by this paper
• Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

  1980cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• 6-APA and the development of the β-lactam antibiotics

  1979cited by this paper
• Effect of clavulanic acid and amoxycillin formulation against beta-lactamase producing Gram-negative bacteria in urinary tract infections.

  1979cited by this paper
• Diagnosis and treatment: drugs five years later. Amoxicillin.

  1979cited by this paper
• 6-APA and the development of the beta-lactam antibiotics.

  1979cited by this paper
• Bronchopulmonary infection due to β-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic acid.

  1978cited by this paper
• Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus

  1977cited by this paper

• Prescribing patterns and clinical perceptions of high-dose co-amoxiclav in upper respiratory tract infections: a nationwide study among otorhinolaryngologists

  2026cites this paper
• Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

  2026cites this paper
• Impact of Excessive Moisture on Amoxycillin Content in Amoxycillin and Potassium Clavulanate Dry Oral Suspensions Marketed in High-Humidity Regions of India: A Pharmacopoeial Study

  2026cites this paper
• Clinical Outcomes and Real-World Effectiveness of Amoxicillin-Clavulanic Acid Across Indian Healthcare Settings: A Retrospective Multicenter Study

  2026cites this paper
• Safety and Clinical Efficacy of High-dose Amoxicillin/Clavulanic Acid in Children with Acute Respiratory Tract Infections in India: A Multicenter Open-label Non-comparative Phase IV Study

  2025cites this paper
• Assessing the potential for non-digestible carbohydrates toward mitigating adverse effects of antibiotics on microbiota composition and activity in an in vitro colon model of the weaning infant

  2025cites this paper
• Differences in Knowledge and Attitudes of Self-Prescription of Antibiotics in Jordan: A Cross-Sectional Study

  2025cites this paper
• Reflecting on Fleming’s caveat: the impact of stakeholder decision-making on antimicrobial resistance evolution

  2025cites this paper
• Physico-chemical and spectroscopic characterization of hyaluronic acid hydrogels crosslinked with 1,4-butanediol diglycidyl ether (BDDE).

  2025cites this paper
• Fulvic acid protects hepatic tissue from amoxicillin/clavulanate-induced hepatotoxicity

  2025cites this paper
• Design, Synthesis, In Vitro, and In Silico Evaluation of Isoxazole–Isoxazoline Conjugates as Potential Antimicrobial Agents

  2025cites this paper
• Direct Effects of Clinically Relevant Antibiotics on Mitochondrial Respiration

  2025cites this paper
• Hepatotoxicity and Antimicrobial Resistance to Amoxicillin and Amoxicillin/Clavulanic Acid: Data Analysis from EudraVigilance

  2025cites this paper
• Clinicians’ Perspectives on the use of Amoxicillin-Clavulanic Acid for Pediatric Respiratory Infections in India Settings

  2025cites this paper
• Development and Validation of Bioanalytical LC–MS/MS Method for Pharmacokinetic Assessment of Amoxicillin and Clavulanate in Human Plasma

  2025cites this paper
• Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro

  2025cites this paper
• Efficacy and safety of a new drug formulation, amoxicillin-clavulanate-cineole, for adult lower respiratory tract infections: a nationwide observational study in Morocco

  2025cites this paper
• Natural product inspired antibiotics approved for human use - 1943 to 2025.

  2025cites this paper
• In silico screening of protein-binding peptides with an application to developing peptide inhibitors against antibiotic resistance

  2024cites this paper
• Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans

  2024cites this paper
• Amoxicillin-clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.

  2024cites this paper
• Discovery of new AMR drugs targeting modulators of antimicrobial activity using in vivo silkworm screening systems

  2024cites this paper
• Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens

  2024cites this paper
• Exploring the Therapeutic Potential of High Dose Co-amoxiclav (1 gm) in Different Clinical Conditions: A Review

  2024cites this paper
• Evaluation of Antibiotics and Antimicrobial Agents for the Suppression of Contamination in in vitro Cannabis (Cannabis sativa L.) Seedlings

  2024cites this paper
• Microalgae-mediated bioremediation: Metabolomic profiling and Adaptive Responses under Amoxicillin-induced stress

  2024cites this paper
• Progress of Photoantibiotics in Overcoming Antibiotic Resistance

  2024cites this paper
• Evaluation of Antibacterial Activity and in vitro Antihistaminic Activity of Two Source Plants of Shalaparni, Desmodium gangeticum, and Desmodium velutinum panchanga Powder

  2024cites this paper
• Efficacy of water extracts of mushrooms on multidrug-resistant bacteria isolated from raw cow milk

  2023cites this paper
• Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries

  2023cites this paper
• A Real-World Perspective of Co-amoxiclav Prescription Pattern With Probiotics for Pediatric Patients With Respiratory Tract Infections: Results of Quantitative and Qualitative Approach in Indian Outpatient Settings.

  2023cites this paper
• Inhibition of β-lactamase function by de novo designed peptide

  2023influential citation
• Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study

  2023influential citation
• Effect of Antibiotics on The Pathogenic Bacteria (K. pneumonia and P. aeruginosa) Isolated Around the Dental Implant Area

  2023cites this paper
• Modulation of the bacterial virulence and resistance by well-known European medicinal herbs.

  2023cites this paper
• Quantitative Evaluation of Antibiotics Use Trend in One Puskesmas in Bengkulu City: ATC/DDD and DU 90% Methods

  2023cites this paper
• Counteracting antibiotic resistance enzymes and efflux pumps.

  2023cites this paper
• Clavulanic Acid and its Potential Therapeutic Effects on the Central Nervous System.

  2023cites this paper
• Quality equivalence and in-vitro antibiotic activity test of different brands of amoxicillin/clavulanic acid tablets in Mwanza, Tanzania: A cross sectional study

  2023cites this paper
• Antibiotics Knowledge, Usage, and Prescription Patterns Among Dental Practitioners in Hyderabad, South India

  2023cites this paper
• Neonatal prophylactic antibiotics after preterm birth affect plasma proteome and immune development in pigs

  2023cites this paper
• Decalogue for the selection of oral antibiotics for lower respiratory tract infections

  2022cites this paper
• Amoxicillin+clavulanic acid in community acquired pneumonia: Past, present, and future from an Indian perspective

  2022cites this paper
• Overcoming Beta-Lactamase-Based Antimicrobial Resistance by Nanocarrier-Loaded Clavulanic Acid and Antibiotic Cotreatments.

  2022cites this paper
• Penicillin allergy that persisted after 66 years: case report

  2022cites this paper
• A RETROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF INJECTION AUGMENTIN IN COVID-19 PATIENTS WITH PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL, TELANGANA

  2022cites this paper
• Deciphering the Role of β-Lactamase Inhibitors, Membrane Permeabilizers and Efflux Pump Inhibitors as Emerging Targets in Antibiotic Resistance

  2022cites this paper
• Design and synthesis of hybrid compounds as novel drugs and medicines

  2022cites this paper
• β-Lactamase Suppression as a Strategy to Target Methicillin-Resistant Staphylococcus aureus: Proof of Concept

  2022cites this paper
• Seguridad en la selección del tratamiento antibiótico oral en las infecciones comunitarias, más allá de la COVID-19

  2021cites this paper
• The Role of Silver Nanoparticles Against Amoxicillin/ Clavulanate-Induced Liver Damage in the Female Rats

  2021cites this paper
• Lacticaseibacillus rhamnosus GG and Saccharomyces cerevisiae boulardii supplementation exert protective effects on human gut microbiome following antibiotic administration in vitro.

  2021cites this paper
• Respiratory-tract infections among geriatrics: prevalence and factors associated with the treatment outcomes

  2021cites this paper
• Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria

  2021cites this paper
• Effects of Thymol on Co-amoxiclav-Induced Hepatotoxicity in Rats

  2021cites this paper
• Molecular Characterization of Bacteria, Detection of Enterotoxin Genes, and Screening of Antibiotic Susceptibility Patterns in Traditionally Processed Meat Products of Sikkim, India

  2021cites this paper
• Modelling and investigation of amoxicillin chemical interaction with mineral waters containing a significant amount of calcium and magnesium salts

  2021cites this paper
• Adherence to National Antimicrobial Guidelines in Hospitalized Geriatric Patients with Community-Acquired Pneumonia: A Prospective Observational study in a Malaysian Hospital

  2021cites this paper
• Medicinal Chemistry of β‐Lactam Antibiotics

  2021cites this paper
• Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens

  2020cites this paper
• Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy

  2020influential citation
• Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282

  2020cites this paper
• Retention of antibiotic activity against resistant bacteria harbouring aminoglycoside-N-acetyltransferase enzyme by adjuvants: a combination of in-silico and in-vitro study

  2020cites this paper
• Therapeutic strategies against autophagic escape by pathogenic bacteria.

  2020cites this paper
• Synergistic Antibacterial Activity Between 1,4-Naphthoquinone and β-Lactam Antibiotics Against Methicillin-Resistant Staphylococcus aureus

  2020cites this paper
• Modulatory Role of Gallic Acid and Vitamin C on Amoxicillin/Clavulanic Acid Combination Induced Hepatotoxicity in Adult Albino Rats

  2020cites this paper
• The bioavailability and pharmacokinetics of an amoxicillin-clavulanic acid granular combination after intravenous and oral administration in swine.

  2020cites this paper
• Antibiotic Sensitivity Of Acute Respiratory Infection Patients In Bhayangkara Hospital Bengkulu.

  2020cites this paper
• Successful treatment of relapsed enterococcal endocarditis with amoxicillin/clavulanate: A case report

  2020cites this paper
• Comparative Purity Study by UV Spectrophotometric and Fourier-Transform Infrared Spectroscopic (FTIR) Techniques for the Simultaneous Determination of Amoxicillin Tri-hydrate Capsules

  2020cites this paper
• Design, synthesis, biological evaluation and in silico studies of certain aryl sulfonyl hydrazones conjugated with 1,3-diaryl pyrazoles as potent metallo-β-lactamase inhibitors.

  2020cites this paper
• Treatment Strategies Against Diabetic Foot Ulcer: Success so far and Road Ahead.

  2020cites this paper
• Repurposing Antibiotics to Treat Resistant Gram‐Negative Pathogens

  2019cites this paper
• β-Lactamases a Inhibitors in the

  2019cites this paper
• The FICI paradigm: Correcting flaws in antimicrobial in vitro synergy screens at their inception

  2019cites this paper
• A Comparative Study of the Efficacy of Intravenous Benzylpenicillin and Intravenous Augmentin in the Empirical Management of Ludwig's Angina

  2019influential citation
• Antibiotic Adjuvants: Make Antibiotics Great Again!

  2019cites this paper
• Toxicity of some broad-spectrum antibacterials in normal rat liver: the role of mitochondrial membrane permeability transition pore

  2019cites this paper
• An investigation of aspects affecting availability and grading of high-risk antibiotics in Sweden.

  2019influential citation
• β-Lactamases and β-Lactamase Inhibitors in the 21st Century

  2019cites this paper
• β-Lactamases and β-Lactamase Inhibitors in the 21st Century. Journal of Molecular Biology.

  2019cites this paper
• Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux‐en‐Y gastric bypass bariatric subjects

  2019cites this paper
• DOSE OPTIMIZATION AND PHARMACOKINETIC / PHARMACODYNAMIC INTEGRATION OF AMOXICILLIN IN LOHI SHEEP ( Ovis aries ) AND BEETAL GOATS ( Capra hircus )

  2018influential citation
• Dissecting bacterial resistance and resilience in antibiotic responses

  2018cites this paper
• Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

  2018cites this paper
• Методичний підхід до обґрунтування раціонального складу військ (сил) Збройних Сил України

  2018cites this paper
• Applying ecological resistance and resilience to dissect bacterial antibiotic responses

  2018cites this paper
• A Natural Deep Eutectic Solvent Formulated to Stabilize β-Lactam Antibiotics

  2018cites this paper
• In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates

  2018cites this paper
• DNA Damage Repair and Drug Efflux as Potential Targets for Reversing Low or Intermediate Ciprofloxacin Resistance in E. coli K-12

  2018cites this paper
• Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

  2018cites this paper
• Damage Repair and Drug Efflux as Potential Targets for Reversing Low or Intermediate Ciprofloxacin Resistance in E . coli K-12 Klitgaard

  2018cites this paper
• The evolution of antibiotic resistance in bacterial colonies

  2017cites this paper
• New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus.

  2017cites this paper
• Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study

  2017cites this paper
• Drug Development for Drug-Resistant Pathogens

  2017cites this paper
• Envelope Structures of Gram-Positive Bacteria.

  2017cites this paper
• Bioequivalence of Two Formulations of Amoxicillin in Human Healthy Volunteers on (HPLC) Technique

  2017cites this paper
• Crystallographic analyses of isoquinoline complexes reveal a new mode of metallo-β-lactamase inhibition.

  2017cites this paper
• Role of Biorelevant Dissolution Media in the Selection of Optimal Salt Forms of Oral Drugs: Maximizing the Gastrointestinal Solubility and in Vitro Activity of the Antimicrobial Molecule, Clofazimine

  2017cites this paper